Wang et al. [51] used a dcas9-HDAC fusion protein to target the DPP4 promoter to reduce its histone acetylation, inhibiting DPP4 expression and significantly reducing tumor growth and metastasis, suggesting a potential therapeutic strategy for chromatin remodeling in metastatic cancer. The gene discussed is DPP4; the disease is metastatic malignant neoplasm.